Half Year 2020 Angle PLC Earnings Call Transcript
Good morning, ladies and gentlemen. Thank you very much for joining ANGLE's interim results webcast call. We're doing this obviously, virtually because of the COVID-19 situation. The COVID-19, of course, had quite a significant impact in the six months to June 30, as it hit towards the end of March. It did cause some disruption within ANGLE, but I'm pleased that we managed to recoup. During that six month period, we had a strong half-year and setup the position for the FDA submission, which followed in the following period, as you know.
We're addressing a large scale market opportunity for liquid biopsy. ANGLE's Parsortix system can play a key role in transforming cancer care for the better. As you know, the whole point here is to have personalized cancer care. The idea is to improve the patient outcome by making sure that they get care, which is targeting their cancer at that particular time, and simultaneously reducing health care costs. And we do that by utilizing Parsortix cassette microfluidic system, as shown in this slide, as Parsortix cassette to separate
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |